A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy HIV-Uninfected Adult Participants
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2016
At a glance
- Drugs HIV DNA vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2016 Status changed from not yet recruiting to recruiting.